Pfizer compound goes to Biogen | March 19, 2018 Issue - Vol. 96 Issue 12 | Chemical & Engineering News
Volume 96 Issue 12 | p. 13 | Concentrates
Issue Date: March 19, 2018

Pfizer compound goes to Biogen

Department: Business
Keywords: Neuroscience, Biogen, Pfizer, schizophrenia

Biogen will pay $75 million for the rights to Pfizer’s AMPA receptor potentiator PF-04958242. The first-in-class compound is meant to address cognitive impairment associated with schizophrenia by improving synaptic transmission. Biogen plans to begin a Phase IIb study of the compound later this year. This sale is the first to be announced since Pfizer said in January that it would end preclinical and early-stage neuroscience drug development.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment